TW202241956A - 新穎抗cd24抗體 - Google Patents

新穎抗cd24抗體 Download PDF

Info

Publication number
TW202241956A
TW202241956A TW111104626A TW111104626A TW202241956A TW 202241956 A TW202241956 A TW 202241956A TW 111104626 A TW111104626 A TW 111104626A TW 111104626 A TW111104626 A TW 111104626A TW 202241956 A TW202241956 A TW 202241956A
Authority
TW
Taiwan
Prior art keywords
seq
variable region
chain variable
light chain
heavy chain
Prior art date
Application number
TW111104626A
Other languages
English (en)
Chinese (zh)
Inventor
陳朋
侯冰
鄧敏
劉芸
羅佳美
宇文輝
單波
建明 梅
Original Assignee
香港商德琪生物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商德琪生物有限公司 filed Critical 香港商德琪生物有限公司
Publication of TW202241956A publication Critical patent/TW202241956A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW111104626A 2021-02-08 2022-02-08 新穎抗cd24抗體 TW202241956A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021076075 2021-02-08
WOPCT/CN2021/076075 2021-02-08
CN202210088172.3 2022-01-25
CN202210088172 2022-01-25

Publications (1)

Publication Number Publication Date
TW202241956A true TW202241956A (zh) 2022-11-01

Family

ID=82741874

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104626A TW202241956A (zh) 2021-02-08 2022-02-08 新穎抗cd24抗體

Country Status (12)

Country Link
US (1) US20240052052A1 (https=)
EP (1) EP4288099A4 (https=)
JP (1) JP2024508672A (https=)
KR (1) KR20230143177A (https=)
CN (1) CN117412770A (https=)
AU (1) AU2022217072A1 (https=)
CA (1) CA3210934A1 (https=)
CO (1) CO2023011463A2 (https=)
IL (1) IL304898A (https=)
MX (1) MX2023009238A (https=)
TW (1) TW202241956A (https=)
WO (1) WO2022170280A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251257A1 (en) * 2023-06-09 2024-12-12 TJ Biopharma (Shanghai) Co., Ltd. Anti-cd24 antibodies and uses thereof
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
WO2025101970A1 (en) * 2023-11-08 2025-05-15 Pheast Therapeutics, Inc. Cd24 antibodies
WO2025128830A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Therapeutic lilrb regulation for treating neurological disorders
WO2025132836A1 (en) * 2023-12-19 2025-06-26 Pentixapharm Ag Antibodies against cd24
WO2025159754A1 (en) * 2024-01-25 2025-07-31 China Medical University Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use
WO2025218729A1 (en) * 2024-04-17 2025-10-23 TJ Biopharma (Shanghai) Co., Ltd. Multifunctional molecules targeting cd24
CN119161485B (zh) * 2024-10-29 2026-03-24 上海中医药大学附属曙光医院 靶向GFRα3的抗体及其制备方法和在抗癌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
ES3012974T3 (en) * 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
KR20210143868A (ko) * 2019-03-26 2021-11-29 포티 세븐, 인코포레이티드 암 치료용 다중특이성 제제
BR112021026133A2 (pt) * 2019-06-25 2022-02-08 Ichilov Tech Ltd Anticorpo anti-cd24 e usos do mesmo

Also Published As

Publication number Publication date
CA3210934A1 (en) 2022-08-11
WO2022170280A3 (en) 2022-09-09
US20240052052A1 (en) 2024-02-15
KR20230143177A (ko) 2023-10-11
CN117412770A (zh) 2024-01-16
EP4288099A2 (en) 2023-12-13
WO2022170280A2 (en) 2022-08-11
MX2023009238A (es) 2023-08-16
CO2023011463A2 (es) 2023-09-18
EP4288099A4 (en) 2025-09-17
JP2024508672A (ja) 2024-02-28
AU2022217072A1 (en) 2023-10-05
IL304898A (en) 2023-10-01
AU2022217072A9 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
AU2019243665B2 (en) Multivalent antibody
CN111133003B (zh) 新型双特异性多肽复合物
CN111108119B (zh) 新型抗CD3ε抗体
TW202241956A (zh) 新穎抗cd24抗體
US20230167177A1 (en) Novel anti-ctla-4 antibody polypeptide
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
WO2021032078A1 (en) Novel anti-sirpa antibodies
JP2023027374A (ja) 抗ｃｄ３抗体及び該抗体を含む分子
TWI754211B (zh) 新型雙特異性cd3/cd20多肽複合物
WO2018147245A1 (ja) 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
US20250270315A1 (en) Novel anti-sirpa antibodies
TW202304997A (zh) 新型抗ｃｄ４抗體
KR20240158351A (ko) Cd3에 특이적인 탈면역화 항체
WO2026041038A1 (en) Novel anti-cdh6 antibodies and uses thereof
EA052500B1 (ru) Новые антитела против cd24
TW202317618A (zh) 新型抗ｃｄ２７６抗體及其用途
TW202413417A (zh) 新穎抗ｃｄ３抗體及其用途
HK40106257A (zh) 新型抗sirpa抗体
CN121605130A (zh) 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体
HK40032023B (en) A novel bispecific cd3/cd20 polypeptide complex